Physician profile
Patrick K Briggs
NPI 1205945839
$133,201.97
in general payments reported to CMS, 2019-2025
34 companies · $19K in 2025
The $19K reported for 2025 was more than what 98% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $8,159 · 2021: $33K · 2022: $29K · 2023: $14K · 2024: $17K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $43K · Consulting Fee: $3,730 · Travel and Lodging: $2,218 · Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $43,119.00 |
| Consulting Fee | $3,730.00 |
| Travel and Lodging | $2,218.03 |
| Food and Beverage | $1,303.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $66,357.84 | 2022-2025 | Motoband |
| Crossroads Extremity Systems, LLC | $45,893.12 | 2019-2021 | |
| Medical Device Business Services, INC. | $6,918.53 | 2022-2023 | |
| Medline Industries Lp | $6,825.07 | 2019-2022 | |
| Fusion Orthopedics USA, LLC | $4,482.37 | 2024-2025 | |
| Ortho Solutions INC | $535.10 | 2023 | |
| Stryker Corporation | $265.29 | 2019 | |
| Tactile Systems Technology INC | $239.66 | 2019-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Kerecis Limited | $233.38 | 2022-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Zimmer Biomet Holdings, INC. | $224.47 | 2022 | |
| Smith+Nephew, INC. | $168.39 | 2020-2023 | Stravix Pl |
| Bone Support INC. | $158.00 | 2021 | |
| Wright Medical Technology, INC. | $98.24 | 2019 | |
| Arthrex, INC. | $88.45 | 2022 | |
| Polynovo North America LLC | $69.35 | 2024 | Novosorb Btm |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $67.79 | 2025 | Restrata Wound Matrix |
| Medtronic, INC. | $64.10 | 2023-2025 | Venaseal |
| Horizon Therapeutics Plc | $61.55 | 2019-2021 | |
| Mimedx Group, INC. | $56.39 | 2025 | |
| Medinc of Texas | $45.38 | 2022-2024 | |
| Integra Lifesciences Corporation | $43.82 | 2019 | |
| Amgen INC. | $42.64 | 2024 | Krystexxa |
| Orthofix Medical, INC. | $34.89 | 2019 | |
| Abbott Laboratories | $34.70 | 2023 | Eterna |
| Kci USA, INC. | $31.42 | 2020-2023 | Activ.A.C., Promogran Prisma |
| Ani Pharmaceuticals, INC. | $27.14 | 2025 | Purified Cortrophin Gel |
| Biogennix, LLC | $25.48 | 2022 | |
| Biotissue Holdings INC. | $24.15 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $21.69 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.80 | 2025 | |
| Pfizer INC. | $15.85 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $15.63 | 2023 | |
| Ossio INC | $13.29 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.